Ventas (VTR) Aandeel Koers
Ventas Koers
De omzet is de afgelopen 19 jaar met 14,9% per jaar gegroeid tot 5,83 Miljard USD. De winst per aandeel is de afgelopen 19 jaar met 4,4% per jaar gedaald. De nettowinstmarge van Ventas ligt op 4,3% en is ten opzichte van 1,3% enkele jaren eerder gestegen. Ventas biedt momenteel een dividendrendement van circa 2,16%. De uitkeringsratio ligt rond 367% van de winst. Het dividend is de afgelopen 19 jaar met 1,0% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 99,00 USD — dat impliceert 11,2% boven de huidige koers. Van de 27 analisten geven 22 het aandeel een koopadvies — per saldo een Kopen-consensus.
Ventas aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Ventas bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Ventas
Ventas Inc is a leading real estate investment trust (REIT) specializing in healthcare properties. The business model of Ventas Inc revolves around owning, operating, and acquiring a diversified portfolio of properties across the healthcare sector. Their primary focus is on leasing and managing healthcare facilities, including senior housing communities, medical offices, hospitals, and research centers. By providing essential real estate solutions to healthcare providers, Ventas Inc generates recurring rental income and long-term value for its shareholders. Through strategic investments and a commitment to innovation, Ventas Inc continues to contribute to the growth and development of the healthcare industry.
Ventas Inc is primarily active in the healthcare real estate sector.
Some of the main competitors of Ventas Inc in the market include Welltower Inc and HCP Inc.
Ventas Inc is a renowned company operating in the real estate investment trust (REIT) sector. Established in 1998 and headquartered in Chicago, Illinois, Ventas specializes in healthcare-related properties. They own and manage a diverse portfolio of premium healthcare facilities, including senior housing communities, medical office buildings, hospitals, and skilled nursing facilities. Ventas has played a pivotal role in transforming the healthcare real estate sector through its strategic acquisitions and investments. With a strong commitment to delivering exceptional care environments, Ventas Inc has become a leading name in the industry, offering investors an opportunity to participate in this thriving sector.
Some significant milestones achieved by Ventas Inc include becoming the first healthcare real estate investment trust (REIT) to be listed on the New York Stock Exchange in 1999. The company also expanded its portfolio through strategic acquisitions, such as the $7.2 billion merger with Nationwide Health Properties in 2011. Additionally, Ventas Inc consistently demonstrated strong financial performance, increasing its annual dividend for 19 consecutive years. The company's commitment to long-term growth and its focus on providing quality healthcare real estate solutions have made Ventas Inc a leader in the industry.
Ventas Inc is primarily present in the United States.
Ventas Inc represents a commitment to integrity, innovation, and excellence in the healthcare real estate industry. The company strives to enhance the lives of seniors and other patients by providing high-quality and transformative healthcare environments. With a focus on sustainable growth and generating long-term value for stakeholders, Ventas Inc employs a philosophy of collaboration, transparency, and ethical business practices. By consistently delivering innovative solutions and maintaining strong relationships with its tenants and partners, Ventas Inc continues to lead the way in the healthcare real estate sector.
Analisten hanteren momenteel een gemiddeld koersdoel van 98,85 USD voor het aandeel Ventas (mediaan: 99,00 USD), oftewel +11,0 % ten opzichte van de laatste koers. De consensus is gebaseerd op 27 analistenratings.
27 analisten beoordelen het aandeel Ventas momenteel: 22 adviseren kopen, 5 houden en 0 verkopen. Voor 2026 verwachten analisten dat Ventas een omzet van 6,95 Miljard USD en winst per aandeel van 0,56 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Ventas op 79,79 EUR (89,04 USD).
Het aandeel Ventas (VTR) is genoteerd aan 7 beurzen, waaronder: NYSE (VTR), London (0LO4.L), SIX (Zürich) (VEN.SW), Frankfurt (VEN.F), München (VEN.MU), Düsseldorf (VEN.DU).
Ventas Inc is a US-based company specializing in healthcare real estate investments. Its business model is based on acquiring and managing properties used by healthcare and senior living facilities. The company is divided into three business segments: Senior Housing Operating Portfolio (SHOP), Medical Office Buildings (MOB), and Life Science Properties (LSP). SHOP includes a wide range of nursing homes and elderly care facilities. Ventas Inc acquires these properties either through facility purchases or by acquiring concession contracts from operators. The company directly operates approximately 110 facilities, making SHOP its highest revenue-generating segment. The MOB segment focuses on acquiring properties used by medical facilities such as doctor's offices, laboratories, and surgical centers. These facilities are often located in complex buildings or campus-like environments and often offer services such as pharmacies, radiology, and rehabilitation. LSP focuses on the real estate needs of life science companies, including biopharmaceutical, biotechnology, and diagnostic companies. The complexity of the properties developed for life science companies requires a high level of expertise and flexibility. Ventas Inc also provides financing and capital structures for the development or acquisition of properties in the SHOP, MOB, and LSP segments. These financing offerings can be tailored to the specific needs of facilities and operators and also include partnerships with other investors. Ventas Inc strives to ensure high-quality and continuous care for patients in its healthcare market through the provision of real estate and financing. The company also emphasizes a long-term growth strategy focused on strengthening operational performance and financial metrics. Overall, Ventas Inc's business model demonstrates a consistent focus on the increasingly important healthcare industry and the needs of patients. With a wide range of real estate offerings and financing options, the company is well-positioned to drive industry growth.
De verwachte omzet van Ventas bedraagt 6,95 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Ventas bedraagt 270,76 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Ventas bedraagt momenteel 158,10. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Ventas-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Ventas bedraagt momenteel 6,16. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Ventas-aandeel.
De Eulerpool Kwaliteitsscore voor Ventas is 4/10.
De ISIN van Ventas is US92276F1003. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Ventas is 878380. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Ventas is VTR. Onder dit beurstickersymbool wordt het Ventas-aandeel op de beurs verhandeld.
Ventas aandeel
Ventas Peer Group
Ventas Ticker
Ventas FIGI
Alle fundamentals en diepgaande analyse van Ventas
Onze aandelenanalyse van het Ventas-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Ventas. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: